LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

Search

Zai Lab Ltd ADR

Geschlossen

BrancheGesundheitswesen

32.51 -5.14

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

32.38

Max

34.29

Schlüsselkennzahlen

By Trading Economics

Einkommen

7.7M

-41M

Verkäufe

3.5M

110M

Gewinnspanne

-37.032

Angestellte

1,869

EBITDA

1.4M

-55M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+48.77% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

11. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-414M

3.8B

Vorheriger Eröffnungskurs

37.65

Vorheriger Schlusskurs

32.51

Nachrichtenstimmung

By Acuity

50%

50%

172 / 372 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Zai Lab Ltd ADR Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

27. Aug. 2025, 22:51 UTC

Ergebnisse

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27. Aug. 2025, 23:57 UTC

Ergebnisse

Trip.com Group 1H Rev $4.01B

27. Aug. 2025, 23:57 UTC

Ergebnisse

Trip.com Group 1H Adj EPS $1.84

27. Aug. 2025, 23:57 UTC

Ergebnisse

Trip.com Group 1H EPS $1.82

27. Aug. 2025, 23:50 UTC

Market Talk

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27. Aug. 2025, 23:39 UTC

Ergebnisse

Correction to Nvidia Earnings Article -- WSJ

27. Aug. 2025, 22:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. Aug. 2025, 22:59 UTC

Market Talk

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27. Aug. 2025, 22:58 UTC

Ergebnisse

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27. Aug. 2025, 22:57 UTC

Ergebnisse

South32 FY Free Cash Flow $192 Million

27. Aug. 2025, 22:56 UTC

Ergebnisse

South32 FY Total Capital Expenditure $1.35 Billion

27. Aug. 2025, 22:56 UTC

Ergebnisse

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27. Aug. 2025, 22:55 UTC

Ergebnisse

South32 Net Cash $123 Million at June 30

27. Aug. 2025, 22:54 UTC

Ergebnisse

South32: Focused on Maintaining Strong Operating Momentum

27. Aug. 2025, 22:53 UTC

Ergebnisse

South32: $144 Million Remains to be Returned to Shareholders Under Program

27. Aug. 2025, 22:53 UTC

Ergebnisse

South32 Extends Capital Management Program for 12 Months

27. Aug. 2025, 22:52 UTC

Ergebnisse

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27. Aug. 2025, 22:51 UTC

Ergebnisse

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27. Aug. 2025, 22:51 UTC

Ergebnisse

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27. Aug. 2025, 22:50 UTC

Ergebnisse

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27. Aug. 2025, 22:50 UTC

Ergebnisse

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27. Aug. 2025, 22:45 UTC

Ergebnisse

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27. Aug. 2025, 22:44 UTC

Ergebnisse

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27. Aug. 2025, 22:44 UTC

Ergebnisse

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27. Aug. 2025, 22:43 UTC

Ergebnisse

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27. Aug. 2025, 22:43 UTC

Ergebnisse

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27. Aug. 2025, 22:42 UTC

Ergebnisse

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27. Aug. 2025, 22:42 UTC

Ergebnisse

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27. Aug. 2025, 22:40 UTC

Ergebnisse

Sandfire Resources Net Debt $123 Million at June 30

27. Aug. 2025, 22:40 UTC

Ergebnisse

Sandfire Resources FY Underlying Ebitda $527.7 Million

Peer-Vergleich

Kursveränderung

Zai Lab Ltd ADR Prognose

Kursziel

By TipRanks

48.77% Vorteil

12-Monats-Prognose

Durchschnitt 51 USD  48.77%

Hoch 69 USD

Tief 35 USD

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Zai Lab Ltd ADR – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

8 ratings

6

Buy

2

Halten

0

Sell

Technischer Score

By Trading Central

28.13 / 31.12Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

172 / 372 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.